VENTURE
Principal Investigator:
Study Sponsor: Upstream Bio, Inc.
Location: HealthPartners Specialty Center
Phase of Study: Phase II
Purpose of study: This study is looking at how effective a new drug called Verekitug is in helping patients with chronic obstructive pulmonary disease (COPD) to breathe better. It is a blinded, randomized, placebo-controlled study, which means that there is 66% chance participants will get Verekitug and a 33% chance they will get a control drug with no active ingredients, and neither the study doctor nor the patient will know until the end of the study what they got. Study participation lasts about 18 to 24 months and involves up to 19 on-site visits and 12 phone visits.
Inclusion Criteria:
To qualify, you must be between the ages of 40 and 85, have moderate-to-severe COPD, and currently be on medication such as Trelegy Ellipta or Spiriva + Pulmicort to treat this condition. (There are many other medications that qualify.) You also must have had one hospitalization for COPD or have had two flare-ups requiring steroids and antibiotics in the past year.
Exclusion Criteria:
You may not be eligible if you have had lung cancer in the past or have had any kind of non-skin cancer in the past 5 years, have severe heart failure, or have had a recent heart attack or stroke.
There are other inclusion and exclusion criteria, so please contact the study team for more information.
Study Contact:
Amanda Gillesby
(952) 967-9369
Amanda.D.Gillesby@HealthPartners.Com
